Pulmonary Hypertension Trial, Recruiting NCT05679206 Sponsor: Insel Gruppe AG, University Hospital Bern Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Pulmonary Hypertension Trial, Recruiting

NCT05679206
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 16 years of age
  • People who have given consent to participate, or for whom a consent waiver has been granted according to the relevant guidelines
  • People who have been diagnosed with preeclampsia, which is defined as new high blood pressure (above 140/90mmHg, measured on more than one occasion, after 20 weeks of pregnancy) combined with at least one of the following:
    • High levels of protein in the urine
    • A low platelet count (below 100,000 per microlitre of blood)
    • Elevated creatinine levels in the blood (a marker of kidney function)
    • Liver enzyme levels at least twice the normal upper limit
    • Fluid in the lungs
    • New and ongoing headache
    • Visual disturbances
  • People who are having their postnatal follow-up care at the obstetrics and cardiology clinic at Inselspital Bern, Switzerland

Who may not be able to join:

  • People who are younger than 16 years of age
  • People whose medical data is incomplete or unclear, where the trial team is unable to confirm eligibility or assess the main outcome of the study, even after attempts to clarify the information

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Emrush Rexhaj, MD, Insel Gruppe AG, Inselspital, Bern

Phone: +41 31 632 21 11

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Insel Gruppe AG, University Hospital Bern
Registry
ClinicalTrials.gov
Start date
20 December 2022
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Changes in systolic pulmonary artery pressure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov